Eli Lilly and Company

Sr. Director - Global Diagnostics Pathways and Policy

Chester, Maryland, United States

Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, HealthcareIndustries

Requirements

Candidates should possess a Bachelor’s degree and a minimum of 4 years of relevant experience in market access and/or policy within the diagnostics space. They must be authorized to work in the United States on a full-time basis.

Responsibilities

The Sr. Director - Global Diagnostics Pathways & Policy will function as a central diagnostic coverage and affordability expert, delivering global strategies to advance diagnostic access and remove barriers to affordability. They will strategically guide and oversee sponsored testing activities, integrate diagnostic pathway and policy insights into launch readiness planning, identify diagnostic coverage and affordability issues for pipeline assets, consult on diagnostic evidence generation planning, monitor the global policy landscape, and oversee key performance initiatives related to diagnostic pathway initiatives. Furthermore, they will collaborate with LVA and Corporate & Government Affairs partners to provide diagnostic policy advisory across the enterprise.

Skills

Diagnostic policy
Pathways strategy
Patient access
Reimbursement ecosystem
Biomarker-directed medicines
Global healthcare strategy

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters
1876Year Founded
$1,180.1MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.
Potential construction delays in Indiana could affect GLP-1 drug production timelines.
Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.
Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.
FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.
Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.
Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI